Wedbush analyst David Nierengarten raised his price target on Outperform-rated Synageva BioPharma (NASDAQ: GEVA) to $111.00 (from $97.00) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE